In recent years, a remarkable advance in the therapy of metastatic melanoma has been achieved with the development of BRAF and MEK inhibitors (BRAFi, MEKi), approved for BRAF-mutant tumors, and monoclonal antibodies targeting T-lymphocyte-associated antigen 4 and programmed cell-death protein 1, approved for both BRAF-mutant and BRAF wild-type melanomas. The gene discussed is BRAF; the disease is metastatic melanoma.